Show simple item record

dc.contributor.authorHagen, Anne Ireneen_US
dc.contributor.authorTretli, Steinaren_US
dc.contributor.authorMæhle, Loviseen_US
dc.contributor.authorApold, Jaranen_US
dc.contributor.authorVedå, Ninaen_US
dc.contributor.authorMøller, Pålen_US
dc.PublishedHereditary Cancer in Clinical Practice 7(1):7eng
dc.description.abstractSeveral studies of survival in women with BRCA1 mutations have shown either reduced survival or no difference compared to controls. Programmes for early detection and treatment of inherited breast cancer, have failed to demonstrate a significant improvement in survival in BRCA1 mutation carriers. One hundred and sixty-seven women with disease-associated germline BRCA1 mutations and breast cancer from 1980 to 2001 were identified. Tumour characteristics, treatment given and survival were recorded. A control group comprising three hundred and four women matched for age, time of diagnosis and stage were used to compare survival. BRCA1 mutation carriers were found to have a poorer prognosis, which could be explained by neither the mode of surgical treatment nor the use of adjuvant chemotherapy. BRCA1 mutation carriers with node negative breast cancer had worse overall survival than controls. Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when diagnosed at an early stage, and that type of treatment does not influence prognosis.en_US
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.titleSurvival in Norwegian BRCA1 mutation carriers with breast canceren_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderAnne Hagen et al.; licensee BioMed Central Ltd.
dc.rights.holderCopyright 2009 Hagen et al; licensee BioMed Central Ltd.
dc.source.journalHereditary Cancer in Clinical Practice

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY